Harvard's faith in Evotec pays off with Janssen diabetes deal
This article was originally published in Scrip
Executive Summary
Harvard University's faith in German drug discovery services company Evotec has paid off. Just over a year ago, the top US academic powerhouse turned to Evotec to add value to its early-stage diabetes assets, in a bid to increase the chance of development success.